iCAD (NASDAQ:ICAD – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both small-cap computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.
Volatility and Risk
iCAD has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and price targets for iCAD and IceCure Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iCAD | 0 | 0 | 0 | 0 | 0.00 |
| IceCure Medical | 0 | 0 | 1 | 1 | 3.50 |
Earnings and Valuation
This table compares iCAD and IceCure Medical”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iCAD | $17.32 million | 3.69 | -$4.85 million | ($0.13) | -18.54 |
| IceCure Medical | $3.23 million | 20.28 | -$14.65 million | ($0.29) | -4.07 |
iCAD has higher revenue and earnings than IceCure Medical. iCAD is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
24.6% of iCAD shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 10.3% of iCAD shares are owned by insiders. Comparatively, 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares iCAD and IceCure Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iCAD | -17.81% | -15.65% | -12.52% |
| IceCure Medical | -376.85% | -124.44% | -87.70% |
Summary
iCAD beats IceCure Medical on 9 of the 15 factors compared between the two stocks.
About iCAD
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
